NASDAQ:CPRX Catalyst Pharmaceuticals (CPRX) Stock Forecast, Price & News $12.17 +0.03 (+0.25%) (As of 09/27/2023 ET) Add Compare Share Share Today's Range$12.02▼$12.3250-Day Range$12.10▼$15.0252-Week Range$11.09▼$22.11Volume675,935 shsAverage Volume1.87 million shsMarket Capitalization$1.30 billionP/E Ratio12.05Dividend YieldN/APrice Target$24.75 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Catalyst Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside103.4% Upside$24.75 Price TargetShort InterestBearish8.67% of Float Sold ShortDividend StrengthN/ASustainability-1.99Upright™ Environmental ScoreNews Sentiment0.61Based on 9 Articles This WeekInsider TradingN/AProj. Earnings Growth68.97%From $0.87 to $1.47 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.67 out of 5 starsMedical Sector97th out of 976 stocksPharmaceutical Preparations Industry26th out of 450 stocks 3.5 Analyst's Opinion Consensus RatingCatalyst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.75, Catalyst Pharmaceuticals has a forecasted upside of 103.4% from its current price of $12.17.Amount of Analyst CoverageCatalyst Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.67% of the float of Catalyst Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCatalyst Pharmaceuticals has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Catalyst Pharmaceuticals has recently increased by 10.89%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCatalyst Pharmaceuticals does not currently pay a dividend.Dividend GrowthCatalyst Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCatalyst Pharmaceuticals has received a 52.55% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Amifampridine" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Catalyst Pharmaceuticals is -1.99. Previous Next 2.6 News and Social Media Coverage News SentimentCatalyst Pharmaceuticals has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Catalyst Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 5 people have searched for CPRX on MarketBeat in the last 30 days. This is a decrease of -62% compared to the previous 30 days.MarketBeat Follows16 people have added Catalyst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Catalyst Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders12.10% of the stock of Catalyst Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.27% of the stock of Catalyst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Catalyst Pharmaceuticals are expected to grow by 68.97% in the coming year, from $0.87 to $1.47 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Catalyst Pharmaceuticals is 12.05, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.63.Price to Earnings Ratio vs. SectorThe P/E ratio of Catalyst Pharmaceuticals is 12.05, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 155.14.Price to Book Value per Share RatioCatalyst Pharmaceuticals has a P/B Ratio of 4.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Catalyst Pharmaceuticals (NASDAQ:CPRX) StockCatalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.Read More CPRX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CPRX Stock News HeadlinesSeptember 27, 2023 | finance.yahoo.comIf EPS Growth Is Important To You, Catalyst Pharmaceuticals (NASDAQ:CPRX) Presents An OpportunitySeptember 25, 2023 | americanbankingnews.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) to Post FY2024 Earnings of $1.33 Per Share, Zacks Research ForecastsSeptember 28, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.September 21, 2023 | marketwatch.comCatalyst Pharmaceuticals Inc. stock falls Thursday, still outperforms marketSeptember 18, 2023 | finance.yahoo.comCatalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare ConferenceSeptember 9, 2023 | seekingalpha.comCatalyst Pharmaceuticals launches $500M mixed shelf offering - filingSeptember 8, 2023 | finance.yahoo.comWhy Is Catalyst (CPRX) Down 14% Since Last Earnings Report?September 8, 2023 | stocknews.comSeptember Buy, Sell or Hold for This Pharma Sock: Catalyst Pharmaceuticals (CPRX)September 28, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.September 6, 2023 | finance.yahoo.comUnraveling the Future of Catalyst Pharmaceuticals Inc (CPRX): A Deep Dive into Key MetricsAugust 30, 2023 | seekingalpha.comCatalyst Pharmaceuticals: The Journey From Earnings Euphoria To Patent PerilsAugust 29, 2023 | stocknews.com3 Pharma Stocks to Watch for Value in SeptemberAugust 24, 2023 | stocknews.com3 Value Pharma Stocks to Keep WatchingAugust 23, 2023 | msn.comCantor Fitzgerald Reiterates Catalyst Pharmaceuticals (CPRX) Overweight RecommendationAugust 21, 2023 | stocknews.comCatalyst Pharmaceuticals (CPRX): Is Now the Time to Buy This Pharma Stock?August 16, 2023 | finance.yahoo.comCatalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung CancerAugust 14, 2023 | finance.yahoo.comCatalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy CongressAugust 12, 2023 | msn.comCantor Fitzgerald Maintains Catalyst Pharmaceuticals (CPRX) Overweight RecommendationAugust 11, 2023 | markets.businessinsider.com5 Analysts Have This to Say About Catalyst PharmaceuticalsAugust 11, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Catalyst Pharma (CPRX)August 11, 2023 | finance.yahoo.comCatalyst Pharmaceuticals Second Quarter 2023 Earnings: EPS: US$0.35 (vs US$0.21 in 2Q 2022)August 10, 2023 | finanznachrichten.deCatalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 9, 2023 | finance.yahoo.comCatalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 3, 2023 | stocknews.comWhich is the Better Value Stock for August: Catalyst Pharmaceuticals, Inc. (CPRX) vs. Teva Pharmaceutical Industries (TEVA)?July 27, 2023 | bizjournals.comPharmaceutical CEO to retire from public company he co-foundedJuly 25, 2023 | finanznachrichten.deCatalyst Pharmaceuticals, Inc.: Patrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-EndJuly 25, 2023 | marketwatch.comCatalyst Pharmaceuticals: Patrick McEnany to Retire as CEO by Year-End >CPRXSee More Headlines Receive CPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CPRX Company Calendar Last Earnings8/09/2023Today9/28/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CPRX CUSIPN/A CIK1369568 Webwww.catalystpharma.com Phone(305) 420-3200Fax305-529-0933Employees82Year Founded2002Price Target and Rating Average Stock Price Forecast$24.75 High Stock Price Forecast$27.00 Low Stock Price Forecast$24.00 Forecasted Upside/Downside+103.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$1.01 Trailing P/E Ratio12.05 Forward P/E Ratio13.99 P/E GrowthN/ANet Income$83.08 million Net Margins38.14% Pretax Margin47.81% Return on Equity36.13% Return on Assets29.63% Debt Debt-to-Equity RatioN/A Current Ratio4.59 Quick Ratio4.38 Sales & Book Value Annual Sales$214.20 million Price / Sales6.06 Cash Flow$0.81 per share Price / Cash Flow14.97 Book Value$2.89 per share Price / Book4.21Miscellaneous Outstanding Shares106,590,000Free Float93,695,000Market Cap$1.30 billion OptionableOptionable Beta1.11 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Patrick J. McEnany (Age 76)Co-Founder, Chairman, Pres & CEO Comp: $1.2MMs. Alicia Grande C.M.A. (Age 52)CPA, CMA, CPA, Chief Accounting Officer, VP, Treasurer & CFO Comp: $667.91kDr. Steven R. Miller Ph.D. (Age 61)COO & Chief Scientific Officer Comp: $809.03kDr. Gary Ingenito M.D. (Age 67)Ph.D., Chief Medical & Regulatory Officer Comp: $751.85kMr. Jeffrey Del Carmen (Age 52)Chief Commercial Officer Comp: $711.7kMs. Mary ColemanVP & Head of Investor RelationsMr. Brian Elsbernd J.D. (Age 59)Chief Compliance Officer & Chief Legal Officer Mr. Pete Curry Sr.VP of SalesDr. Stanley Iyadurai M.D.Ph.D., Sr. VP of Medical Affairs & Drug DiscoveryDr. Preethi Sundaram Ph.D. (Age 47)Chief Strategy Officer More ExecutivesKey CompetitorsStructure TherapeuticsNASDAQ:GPCRSummit TherapeuticsNASDAQ:SMMTAmneal PharmaceuticalsNYSE:AMRXAmylyx PharmaceuticalsNASDAQ:AMLXTG TherapeuticsNASDAQ:TGTXView All CompetitorsInsiders & InstitutionsBarclays PLCBought 468,846 shares on 9/21/2023Ownership: 0.622%Virginia Retirement Systems ET ALBought 67,300 shares on 8/22/2023Ownership: 0.063%California State Teachers Retirement SystemSold 2,554 shares on 8/21/2023Ownership: 0.113%Teachers Retirement System of The State of KentuckyBought 1,661 shares on 8/21/2023Ownership: 0.030%VisionPoint Advisory Group LLCBought 3,176 shares on 8/21/2023Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions CPRX Stock - Frequently Asked Questions Should I buy or sell Catalyst Pharmaceuticals stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CPRX shares. View CPRX analyst ratings or view top-rated stocks. What is Catalyst Pharmaceuticals' stock price forecast for 2023? 4 analysts have issued 1 year price objectives for Catalyst Pharmaceuticals' shares. Their CPRX share price forecasts range from $24.00 to $27.00. On average, they predict the company's stock price to reach $24.75 in the next year. This suggests a possible upside of 103.4% from the stock's current price. View analysts price targets for CPRX or view top-rated stocks among Wall Street analysts. How have CPRX shares performed in 2023? Catalyst Pharmaceuticals' stock was trading at $18.60 at the start of the year. Since then, CPRX stock has decreased by 34.6% and is now trading at $12.17. View the best growth stocks for 2023 here. Are investors shorting Catalyst Pharmaceuticals? Catalyst Pharmaceuticals saw a increase in short interest in September. As of September 15th, there was short interest totaling 7,940,000 shares, an increase of 10.9% from the August 31st total of 7,160,000 shares. Based on an average daily trading volume, of 1,290,000 shares, the days-to-cover ratio is currently 6.2 days. Currently, 8.7% of the shares of the stock are sold short. View Catalyst Pharmaceuticals' Short Interest. When is Catalyst Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our CPRX earnings forecast. How were Catalyst Pharmaceuticals' earnings last quarter? Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) posted its quarterly earnings results on Wednesday, August, 9th. The biopharmaceutical company reported $0.33 EPS for the quarter, topping the consensus estimate of $0.25 by $0.08. The biopharmaceutical company earned $99.58 million during the quarter, compared to analysts' expectations of $92.77 million. Catalyst Pharmaceuticals had a trailing twelve-month return on equity of 36.13% and a net margin of 38.14%. What ETFs hold Catalyst Pharmaceuticals' stock? ETFs with the largest weight of Catalyst Pharmaceuticals (NASDAQ:CPRX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Invesco Biotechnology & Genome ETF (PBE), Janus Henderson Small Cap Growth Alpha ETF (JSML), SPDR S&P Biotech ETF (XBI), Invesco S&P SmallCap Health Care ETF (PSCH), ERShares NextGen Entrepreneurs ETF (ERSX), Invesco S&P SmallCap 600 Pure Growth ETF (RZG) and ALPS Medical Breakthroughs ETF (SBIO). What guidance has Catalyst Pharmaceuticals issued on next quarter's earnings? Catalyst Pharmaceuticals issued an update on its FY 2023 earnings guidance on Thursday, August, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $380.00 million-$390.00 million, compared to the consensus revenue estimate of $380.21 million. What other stocks do shareholders of Catalyst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD). What is Catalyst Pharmaceuticals' stock symbol? Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX." Who are Catalyst Pharmaceuticals' major shareholders? Catalyst Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (14.88%), State Street Corp (8.87%), Dimensional Fund Advisors LP (2.32%), Geode Capital Management LLC (1.81%), Northern Trust Corp (1.32%) and Goldman Sachs Group Inc. (1.17%). Insiders that own company stock include Alicia Grande, Brian Elsbernd, Carmen Jeffrey Del, Charles B O'keeffe, David S Tierney, Donald A Denkhaus, Gary Ingenito, Patrick J Mcenany, Philip H Coelho, Preethi Sundaram and Steve Miller. View institutional ownership trends. How do I buy shares of Catalyst Pharmaceuticals? Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Catalyst Pharmaceuticals' stock price today? One share of CPRX stock can currently be purchased for approximately $12.17. How much money does Catalyst Pharmaceuticals make? Catalyst Pharmaceuticals (NASDAQ:CPRX) has a market capitalization of $1.30 billion and generates $214.20 million in revenue each year. The biopharmaceutical company earns $83.08 million in net income (profit) each year or $1.01 on an earnings per share basis. How can I contact Catalyst Pharmaceuticals? Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The official website for the company is www.catalystpharma.com. The biopharmaceutical company can be reached via phone at (305) 420-3200, via email at bkorb@troutgroup.com, or via fax at 305-529-0933. This page (NASDAQ:CPRX) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.